恒瑞 1 类新药新适应症报上市,治疗血小板减少

新浪医药
Aug 12

8 月 11 日,CDE 官网显示,恒瑞海曲泊帕乙醇胺片新适应症上市申请获受理。根据临床试验进展,业内推测用于肿瘤化疗所致血小板减少症(CIT)。来源:CDE 官网海曲泊帕乙醇胺片是恒瑞医药研发的 1 类创新药,也是中国首个自主研发的非肽类口服血小板生成素受体激动剂,通过激活 TPO-R 介导的 STAT 和 MAPK 信号转导通路,促进血小板生成。海曲泊帕乙醇胺片于 2021 年在中国获批上市并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10